Aim: To evaluate the long-term cost-effectiveness of fixed-ratio combination insulin degludec/ liraglutide (IDegLira) versus comparator regimens for type 2 diabetes in Spain, based on realworld evidence.
controlled trials (RCTs), IDegLira has been shown to result in superior glycaemic control, significant weight loss and lower risk of hypoglycaemia compared with basal insulin and basal-bolus insulin regimens. 3, 4 Similarly, IDegLira has been shown to offer improved glycaemic control versus a GLP-1 receptor agonist regimen and versus the combination of GLP-1 receptor agonists with insulin (indirectly, not in a fixed ratio combination). 5, 6 In addition to the valuable data provided by RCTs, real-world evidence providing insights into effectiveness and safety in routine clinical practice is playing an increasingly important role in healthcare decision-making. 7 The first large, multi-country real-world evidence on IDegLira was recently published by Price et al 8 
from the European Xultophy Treatment Retrospective
Audit (EXTRA) study. EXTRA was a multicentre, retrospective chart review in 611 adults with type 2 diabetes, who started IDegLira ≥6 months before data collection. After 6 months of IDegLira treatment, significant reductions in glycated haemoglobin (HbA1c) were observed in the overall population (−10 mmol/mol [−0.9%]; P < 0.0001) and in all subgroups defined by prior therapy. Improved glycaemic control was accompanied by a significant reduction in mean body weight (−0.7 kg; P = 0.0127) and an 82% reduction in hypoglycaemia rates (rate ratio 0.18; P < 0.0001).
Diabetes represents a serious healthcare challenge in Spain, where Soriguer et al 9 reported an overall national prevalence of diabetes mellitus of 13.8% (95% confidence interval [CI] 12.8, 14.7) from the di@bet.
es Study. Mata-Cases et al 10 
| Simulated cohort and treatment effects
Cohort characteristics and treatment effects were derived from the pre-treatment subgroups of the effectiveness analysis set in the EXTRA study, which included all patients in the full analysis set who continued IDegLira for at least 6 months after initiation. Based on pre-study therapy, four simulation cohorts were generated for the modelling analysis, each of which corresponded to a subgroup in the EXTRA study ( Table 1 ). The effect of IDegLira on clinical risk factors after 6 months was applied in the modelling analysis (in line with the primary endpoint in the EXTRA study), and was compared with continuing the baseline therapy (assuming no further changes in risk factors whilst on the same therapy; Table 2 ). Changes in hypoglycaemia rates were conservatively not included in the base-case analysis (but were investigated in sensitivity analyses) as rates were consistently low and not anticipated to notably influence cost-effectiveness outcomes.
All treatments were assumed to be continued for 5 years in the modelling analysis, before intensification to therapy equivalent to the MDI subgroup (assumed to be basal-bolus therapy for most patients) in line with previously published economic evaluations of IDegLira. 16, 17 No further intensification steps were modelled. Treatment effects on HbA1c
and body mass index (BMI) were assumed to persist for the 5 years of IDegLira therapy, before reverting back to baseline levels at intensification (making it the same in both the IDegLira and comparator arms).
Long-term progression of systolic blood pressure was modelled based on the UK Prospective Diabetes Study (UKPDS) data in all treatment arms, and serum lipid levels were modelled based on data from the Framingham Heart Study. (Table S1 ). In certain subgroups, a proportion of patients received prandial insulin therapy concomitant to IDegLira, and this was captured in the estimates of annual treatment costs (using the cost of insulin aspart). In the MDI subgroup,~33% of patients took prandial insulin after the initiation of IDegLira; in the basal insulin subgroup this value was 3% and in the GLP-1 receptor agonist in combination with insulin group it was 16%.
Costs associated with diabetes-related complications were derived from a literature review and searches of Spanish diagnosisrelated group data. [18] [19] [20] Costs were inflated to 2016 EUR values if required using the Spanish consumer price index for health. 21 Qualityof-life utilities associated with type 2 diabetes and its complications were taken from published sources, and are consistent with previously published cost-effectiveness analyses. 3 | RESULTS
| IDegLira versus MDI

Model projections indicated that improved glycaemic control with
IDegLira led to fewer diabetes-related complications than MDI therapy over patients' lifetimes ( Figures S1 and S2 ). This led to an improvement in quality-adjusted life expectancy of 0.14 qualityadjusted life-years (QALYs) with IDegLira versus MDI (Table 3) . A similar survival benefit was observed with IDegLira over MDI FIGURE 1 Breakdown of direct costs by cost category. Costs were categorized as treatment costs (costs associated with diabetes therapy), management costs (associated with routine care) and complication costs (associated with cardiovascular, renal, diabetic foot or neuropathy, or ocular complications). The price of IDegLira in Spain has not been approved by the Ministry of Health at the time of publication. EUR, 2016 Euros; GLP-1, glucagon-like peptide-1; IDegLira, fixed-ratio combination insulin degludec/liraglutide; MDI, multiple daily insulin injections (0.14 years). Lifetime costs were higher by EUR 418 on IDegLira than on MDI therapy (EUR 58 304 vs 57 889), with higher pharmacy costs in the IDegLira arm partly offset by the reduced costs of diabetesrelated complications (Figure 1 ). IDegLira was associated with an ICER of EUR 3013 per QALY gained versus MDI.
| GLP-1 receptor agonist in combination with insulin
IDegLira was also projected to improve clinical outcomes in the comparison with GLP-1 receptor agonists in combination with insulin regimens.
Benefits in terms of glycaemic control with IDegLira were associated with fewer diabetes-related complications and improvements in qualityadjusted life expectancy (by 0.22 QALYs) and life expectancy (0.27 years)
versus GLP-1 receptor agonists in combination with insulin (Table 3, Figures S1 and S2). Mean total costs were lower with IDegLira by approximately EUR 3742 per patient, as a result of reduced complication costs and lower pharmacy costs versus continuing GLP-1 receptor agonists in combination with insulin therapy. As a result, IDegLira was considered dominant to GLP-1 receptor agonists in combination with insulin (cost and life saving) over patient lifetimes (therefore no ICER is presented).
| Basal insulin
The clinical benefits with IDegLira were more marked in comparison with basal insulin therapy. Reduced complication rates and a delayed onset of most diabetes-related complications meant that IDegLira was associated with an improvement in quality-adjusted life expectancy of 0.25 QALYs versus basal insulin (Table 3 , Figures S1 and S2) . IDegLira was also associated with an improvement in life expectancy (0.28 years) over basal insulin. Higher pharmacy costs with IDegLira resulted in total direct costs being EUR 1707 higher than for basal insulin on average, despite lower diabetes-related complication costs. IDegLira was associated with an ICER of EUR 6890 per QALY gained versus basal insulin.
| GLP-1 receptor agonist therapy
In the comparison with GLP-1 receptor agonist therapy, improved glycaemic control with IDegLira was also projected to lead to benefits in 
| Sensitivity analyses
Sensitivity analyses showed that the HbA1c benefits associated with IDegLira were a key driver of cost-effectiveness in all four scenarios ( (Tables S2   and S4 ). In the comparisons with GLP-1 receptor agonists and GLP-1 receptor agonists in combination with insulin, IDegLira remained dominant in all sensitivity analyses (Tables S3 and S5 ). Probabilistic sensitivity analysis showed that, assuming a willingness to pay of EUR 30 000 per QALY gained, the probabilities that IDegLira would be considered cost-effective were: 58.6% versus MDI; 59.6% versus basal insulin;
76.6% versus GLP-1 receptor agonists; and 74.0% versus GLP-1 receptor agonists in combination with insulin therapy (Figure 2 , Figure S4 ).
| DISCUSSION
Based on the findings of the EXTRA study, the present modelling analysis provides evidence that IDegLira is likely to reduce the incidence The use of data from a single-arm study to model long-term outcomes can be considered a limitation of the analysis. Ideally, the modelling analysis would be based on several years of prospectively collected data from large-scale cohorts on IDegLira and multiple comparator regimens; however, this type of data is rarely available, particularly for modern interventions that are relatively new to the market.
In the absence of such data, studies like EXTRA provide valuable information on the impact of therapy in the real-world setting and it is interesting to note that the results of the present evaluation were consistent with evaluations based on prospectively collected RCT data. A further criticism of the present analysis could be the use of short-term clinical data (6 months after IDegLira initiation in the EXTRA study) to inform long-term projections. However, in the absence of long-term data, projections using published and validated health economic models represent the best approach available for informing healthcare decision-making. As with any modelling study, particularly those in type 2 diabetes, simplifying assumptions were a necessary part of the analysis. In the present study, IDegLira was assumed to fit into the treatment algorithm at the same stage as basal insulin therapy, and was therefore compared directly with basal insulin therapy and treatment options adjacent to it in the algorithm. It was assumed that treatment with IDegLira and comparators was for a duration of 5 years before intensification to basal-bolus insulin therapy (in line with the treatment algorithm), assumed to be the same as MDI treatment in the present analysis. This duration of therapy was consistent with previously published economic evaluations of IDegLira, although longterm data supporting the durability of IDegLira therapy are not currently available. 16, 17 Importantly, in terms of cost-effectiveness, the present analysis balances the additional costs of therapy with the additional clinical benefits of therapy over the same 5-year duration.
As a result, assumptions of shorter or longer treatment duration before intensification are likely to produce similar outcomes in terms of cost-effectiveness, provided the assumption that additional costs and clinical benefits are applied for an equal duration (i.e. costs are not applied for a shorter duration than clinical benefits) is maintained.
The EXTRA study provided evidence that IDegLira improves glycaemic control relative to a range of GLP-1 receptor agonist and insulin regimens. In this health economic analysis for Spain, the benefits of IDegLira were projected to improve long-term clinical outcomes and be cost-saving or cost-effective for patients with type 2 diabetes previously treated with MDI, GLP-1 receptor agonists in combination with insulin, basal insulin or GLP-1 receptor agonist therapy.
